WallStSmart

Fortress Biotech Inc Pref Series A (FBIOP)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 103861% more annual revenue ($65.77B vs $63.26M). MRK leads profitability with a 13.6% profit margin vs 10.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

FBIOP

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 5.0Value: 5.3Quality: 6.0
Piotroski: 4/9Altman Z: -4.86

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FBIOPUndervalued (+13.2%)

Margin of Safety

+13.2%

Fair Value

$13.03

Current Price

$20.43

$7.40 discount

UndervaluedFair: $13.03Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FBIOP1 strengths · Avg: 10.0/10
Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

FBIOP4 concerns · Avg: 3.3/10
Price/BookValuation
12.8x4/10

Trading at 12.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$77.81M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
-4.862/10

Distress zone — elevated risk

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : FBIOP

The strongest argument for FBIOP centers on Return on Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : FBIOP

The primary concerns for FBIOP are Price/Book, EPS Growth, Market Cap.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

FBIOP carries more volatility with a beta of 1.16 — expect wider price swings.

FBIOP is growing revenue faster at 6.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 28/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fortress Biotech Inc Pref Series A

HEALTHCARE · BIOTECHNOLOGY · USA

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?